NASDAQ:AEZS Aeterna Zentaris (AEZS) Stock Price, News & Analysis → Man who spotted Apple at $1.49 says: “Buy These 6 AI Stocks.” (From InvestorPlace) (Ad) Free AEZS Stock Alerts $8.52 -0.07 (-0.81%) (As of 05/17/2024 ET) Add Compare Share Share Today's Range$8.51▼$8.6850-Day Range$7.52▼$8.7652-Week Range$5.44▼$12.80Volume5,648 shsAverage Volume8,354 shsMarket Capitalization$10.31 millionP/E RatioN/ADividend YieldN/APrice Target$60.00 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesSEC FilingsShort InterestSocial Media Get Aeterna Zentaris alerts: Email Address Aeterna Zentaris MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside604.2% Upside$60.00 Price TargetShort InterestHealthy0.34% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.20Based on 7 Articles This WeekInsider TradingN/AProj. Earnings GrowthN/ASee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.2.30 out of 5 starsMedical Sector524th out of 920 stocksPharmaceutical Preparations Industry243rd out of 429 stocks 3.5 Analyst's Opinion Consensus RatingAeterna Zentaris has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.Amount of Analyst CoverageAeterna Zentaris has received no research coverage in the past 90 days.Read more about Aeterna Zentaris' stock forecast and price target. Previous Next 5.0 Short Interest Percentage of Shares Shorted0.34% of the float of Aeterna Zentaris has been sold short.Short Interest Ratio / Days to CoverAeterna Zentaris has a short interest ratio ("days to cover") of 0.9, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Aeterna Zentaris has recently decreased by 75.74%, indicating that investor sentiment is improving significantly. Previous Next 0.0 Dividend Strength Dividend YieldAeterna Zentaris does not currently pay a dividend.Dividend GrowthAeterna Zentaris does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for AEZS. Previous Next 1.8 News and Social Media Coverage News SentimentAeterna Zentaris has a news sentiment score of 0.20. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.42 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 7 news articles for Aeterna Zentaris this week, compared to 0 articles on an average week. Previous Next 0.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Aeterna Zentaris insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 0.10% of the stock of Aeterna Zentaris is held by insiders.Percentage Held by InstitutionsOnly 0.73% of the stock of Aeterna Zentaris is held by institutions.Read more about Aeterna Zentaris' insider trading history. Previous Next 0.6 Earnings and Valuation Price to Earnings Ratio vs. the MarketThe P/E ratio of Aeterna Zentaris is -0.57, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Aeterna Zentaris is -0.57, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioAeterna Zentaris has a P/B Ratio of 0.57. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.Read more about Aeterna Zentaris' valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Crypto 101 MediaShocking $16T Elon Musk Crypto LeakReports of a leaked meeting between Elon Musk and staff at X.com could send shockwaves through the crypto market. Musk revealed a "mind-blowing" plan to take over the global payment system. In his own words, the world's richest man said "you won't need a bank account." Prominent voices in crypto believe what comes next will mirror a crypto mass adoption similar to the one that triggered bitcoin's last bull run.Click here now to get your copy. About Aeterna Zentaris Stock (NASDAQ:AEZS)Aeterna Zentaris Inc., a specialty biopharmaceutical company, engages in developing and commercializing therapeutics and diagnostic tests. Its lead product is Macrilen (macimorelin), an orally available peptidomimetic ghrelin receptor (GHSR-1a) agonist that stimulates the secretion of growth hormone by binding to the GHSR-1a for the diagnosis of adult growth hormone deficiency and childhood-onset growth hormone deficiency, as well as oncology indications; and AEZS-150, a delayed clearance parathyroid hormonefusion polypeptide that is in preclinical trail for the treatment of hypoparathyroidism in adults. Aeterna Zentaris Inc. has a license agreement with University of Wuerzburg to research, develop, manufacture, and sell a potential COVID-19 vaccine; development, manufacture, and commercialization of the treatment for neuromyelitis optica spectrum disorder; and for pre-clinical development towards the potential treatment of Parkinson's disease. It also has a license agreement with Consilient Health Ltd. and NK MEDITECH Ltd. for the development and commercialization of macimorelin in the Republic of Korea; a distribution and commercialization agreement with Er-Kim Pharmaceuticals Bulgaria EOOD for the commercialization of macimorelin for the diagnosis of growth hormone deficiency in children and adults in Turkey and some non-European Union Balkan countries; as well as The University of Sheffield, the United Kingdom for the research, development, manufacture, and commercialization of parathyroid hormone fusion polypeptides for the treatment of primary hypoparathyroidism. Aeterna Zentaris Inc. was incorporated in 1990 and is headquartered in Summerville, South Carolina.Read More AEZS Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart AEZS Stock News HeadlinesMay 17 at 8:05 AM | finance.yahoo.comAeterna Zentaris Announces Details Regarding Transaction with CeaproMay 17 at 8:00 AM | globenewswire.comAeterna Zentaris Announces Details Regarding Transaction with CeaproMay 16 at 3:26 AM | americanbankingnews.comAeterna Zentaris (NASDAQ:AEZS) Receives New Coverage from Analysts at StockNews.comMay 15, 2024 | finanznachrichten.deAeterna Zentaris Inc: Aeterna Zentaris Reports First Quarter 2024 Financial ResultsMay 14, 2024 | washingtonpost.comAeterna Zentaris: Q1 Earnings SnapshotMay 14, 2024 | globenewswire.comAeterna Zentaris Reports First Quarter 2024 Financial ResultsMay 11, 2024 | americanbankingnews.comAeterna Zentaris Inc. (NASDAQ:AEZS) Short Interest UpdateMay 1, 2024 | globenewswire.comAeterna Zentaris Announces Effective Date of Share ConsolidationApril 28, 2024 | finance.yahoo.com12 ChatGPT Penny Stock Picks Right NowApril 2, 2024 | theglobeandmail.comAuxly Cannabis Group: Top 10 Undervalued Healthcare Sector Stocks on TSX (XLY)March 28, 2024 | globenewswire.comCeapro Receives Final Court Approval for Merger with Aeterna ZentarisMarch 27, 2024 | benzinga.comAEterna Zentaris: Q4 Earnings InsightsMarch 27, 2024 | globenewswire.comAeterna Zentaris Reports Fourth Quarter and Full Year 2023 Financial Results and Announces Completion of Enrollment in Ongoing Pivotal DETECT-Trial for the Diagnosis of Childhood-Onset Growth Hormone DeficiencyMarch 13, 2024 | finanznachrichten.deAeterna Zentaris Inc: Aeterna Zentaris and Ceapro Merger Approved by Securityholders at Special MeetingsMarch 12, 2024 | globenewswire.comAeterna Zentaris and Ceapro Merger Approved by Securityholders at Special MeetingsFebruary 28, 2024 | thestreet.comAeterna Zentaris Inc.February 26, 2024 | globenewswire.comLeading Independent Proxy Advisory Firm ISS Recommends Aeterna Zentaris and Ceapro Securityholders Vote FOR the Arrangement Agreement to Approve the Merger of Equals to Create a Diversified Biopharmaceutical CompanyFebruary 15, 2024 | globenewswire.comAeterna Zentaris Issues Letter to Shareholders and Management Proxy Circular Ahead of Special Meeting of Shareholders to Approve Merger of Equals with CeaproNovember 14, 2023 | morningstar.comAEterna Zentaris Inc AEZSNovember 9, 2023 | msn.comAeterna Zentaris GAAP EPS of -$0.85November 9, 2023 | finance.yahoo.comAeterna Zentaris Reports Third Quarter 2023 Financial ResultsNovember 6, 2023 | theglobeandmail.comAEterna Zentaris: Stocks trading at Less Than Cash Value on TSX (AEZS)October 30, 2023 | theglobeandmail.comAEterna Zentaris: Top 10 Undervalued Biotechnology Industry Stocks (AEZS)October 11, 2023 | finance.yahoo.comAeterna Zentaris to Participate at the Virtual Investor Ask the CEO ConferenceSeptember 12, 2023 | theglobeandmail.comClosing Bell: Aeterna Zentaris Inc down on Monday (AEZS)See More Headlines Receive AEZS Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Aeterna Zentaris and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings3/27/2024Today5/19/2024Next Earnings (Estimated)8/14/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:AEZS CUSIPN/A CIK1113423 Webwww.zentaris.com Phone(418) 652-8525Fax418-948-9191Employees11Year FoundedN/APrice Target and Rating Average Stock Price Target$60.00 High Stock Price Target$60.00 Low Stock Price Target$60.00 Potential Upside/Downside+604.2%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage1 Analysts Profitability EPS (Most Recent Fiscal Year)($14.86) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-16,550,000.00 Net Margins-760.32% Pretax Margin-367.99% Return on Equity-73.62% Return on Assets-42.98% Debt Debt-to-Equity RatioN/A Current Ratio8.01 Quick Ratio8.00 Sales & Book Value Annual Sales$4.50 million Price / Sales2.29 Cash FlowN/A Price / Cash FlowN/A Book Value$14.99 per share Price / Book0.57Miscellaneous Outstanding Shares1,210,000Free Float1,213,000Market Cap$10.31 million OptionableNo Data Beta1.60 Social Links 12 Stocks Corporate Insiders are AbandoningIf a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know?Get This Free Report Key ExecutivesDr. Klaus Paulini Ph.D.President, CEO & Executive DirectorMr. Giuliano La FrattaSenior VP of Finance & CFODr. Michael Teifel Ph.D.Senior VP of Non-Clinical Development & Chief Scientific OfficerDr. Nicola Ammer M.D.Chief Medical Officer & Senior VP of Clinical DevelopmentDr. Matthias GerlachSenior Vice President Manufacturing & Supply ChainKey CompetitorsAddex TherapeuticsNASDAQ:ADXNNuCanaNASDAQ:NCNAAlterity TherapeuticsNASDAQ:ATHEMolecular TemplatesNASDAQ:MTEMGuardion Health SciencesNASDAQ:GHSIView All Competitors AEZS Stock Analysis - Frequently Asked Questions Should I buy or sell Aeterna Zentaris stock right now? 1 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Aeterna Zentaris in the last twelve months. There are currently 1 buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" AEZS shares. View AEZS analyst ratings or view top-rated stocks. What is Aeterna Zentaris' stock price target for 2024? 1 brokers have issued 1-year price objectives for Aeterna Zentaris' shares. Their AEZS share price targets range from $60.00 to $60.00. On average, they expect the company's share price to reach $60.00 in the next twelve months. This suggests a possible upside of 604.2% from the stock's current price. View analysts price targets for AEZS or view top-rated stocks among Wall Street analysts. How have AEZS shares performed in 2024? Aeterna Zentaris' stock was trading at $7.44 at the beginning of the year. Since then, AEZS shares have increased by 14.5% and is now trading at $8.52. View the best growth stocks for 2024 here. When is Aeterna Zentaris' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Wednesday, August 14th 2024. View our AEZS earnings forecast. How were Aeterna Zentaris' earnings last quarter? Aeterna Zentaris Inc. (NASDAQ:AEZS) issued its earnings results on Wednesday, March, 27th. The biopharmaceutical company reported ($4.64) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($3.88) by $0.76. The biopharmaceutical company had revenue of $0.12 million for the quarter. Aeterna Zentaris had a negative trailing twelve-month return on equity of 73.62% and a negative net margin of 760.32%. When did Aeterna Zentaris' stock split? Aeterna Zentaris shares reverse split on the morning of Friday, May 3rd 2024. The 1-4 reverse split was announced on Friday, May 3rd 2024. The number of shares owned by shareholders was adjusted after the closing bell on Friday, May 3rd 2024. An investor that had 100 shares of stock prior to the reverse split would have 25 shares after the split. What other stocks do shareholders of Aeterna Zentaris own? Based on aggregate information from My MarketBeat watchlists, some companies that other Aeterna Zentaris investors own include Zosano Pharma (ZSAN), Pennsylvania Real Estate Investment Trust (PEI), CBL & Associates Properties (CBL), CNBX Pharmaceuticals (CNBX), Matinas BioPharma (MTNB), ADMA Biologics (ADMA), Bionano Genomics (BNGO), Novan (NOVN) and Washington Prime Group (WPG). Who are Aeterna Zentaris' major shareholders? Aeterna Zentaris' stock is owned by a number of retail and institutional investors. Top institutional shareholders include Concourse Financial Group Securities Inc. (0.00%). How do I buy shares of Aeterna Zentaris? Shares of AEZS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:AEZS) was last updated on 5/19/2024 by MarketBeat.com Staff From Our PartnersBuy this small stock before coming AI Tidal WaveChaikin AnalyticsCEO of Biggest AI Chipmaker Just Dropped a Bombshell…Banyan Hill PublishingShocking $16T Elon Musk Crypto LeakCrypto 101 MediaForget Bitcoin: This $8 Stock Is the Next Big ThingBehind the MarketsDems have chosen Biden replacement?Paradigm PressHow Biden has already won 2024Porter & CompanyExposed: 10 CENT Crypto to Explode May 20th?True Market InsidersA letter is coming from the "Bureau of the Fiscal Service".Stansberry Research Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Aeterna Zentaris Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.